Anthem Biosciences Ltd management interview: Anthem Biosciences Adds Two Big Pharma Clients: Revenue Ramp-Up Expected In FY27 | Business News
ET Now, 2026-11-04. Video: https://www.youtube.com/watch?v=rnXTVd0WwS0
- CRDMO recovery: Revenue grew 9.25%, though first-half revenue remained lower year on year. After growing 42% quarter on quarter as it caught up from Q1, the business expects further catch-up over the next 2 quarters and remains confident of delivering its growth outlook by year-end.
- Order book: The order-book position was unchanged from July, when it represented nearly 60% of FY27 orders. Anthem typically ends the year with orders covering 50 to 60% of the following year’s orders, with some spillover now extending into the next year.
- Big pharma clients: Anthem said it had signed on 2 big clients in the quarter; revenues are expected to start in the next 2 quarters, with the main build-up next year. The pace will depend on how the clients’ programs progress.
- Specialty ingredients: The business was flat because it competes with CRDMO for capacity, and rapid CRDMO growth can mute its results. Management expects specialty ingredients to pick up and grow by year-end.
- Phase 3 launches: Of the late-stage molecules discussed, one product was approved, with revenues expected to start in the next 2 quarters. Management cautioned that novel launches build slowly, with greater revenue potential once global launches gain traction.